A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

Auron will present acute myeloid leukemia (AML) cell line-based activity, as well as ex vivo and in vivo patient derived xenograft data from AUTX-703, its oral, potent and selective degrader targeting ...

The poster will be presented at the 39th Annual Society for Immunotherapy ... in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells. Published first on TheFly – ...

Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Among the most inspired choices for a 4K restoration this year would have to be Alan Rudolph’s Breakfast of Champions. Despite coming out in the middle of Bruce Willis’ Armageddon/The Sixth Sense ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Due to very limited normal tissue expression, B7-H7xCD3 is safe to administer in a wide dose range. Efficacy data presented at SITC demonstrates potent T cell-mediated cytotoxicity against multiple B7 ...

The Tokyo structure's dismantling in 2022 saw a number of its capsules repurposed globally - even at Hong Kong's M+ - ...